US Stock MarketDetailed Quotes

NUVL Nuvalent

Watchlist
  • 91.430
  • -2.960-3.14%
Trading Nov 12 15:47 ET
6.45BMarket Cap-32770P/E (TTM)

About Nuvalent Company

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Company Profile

SymbolNUVL
Company NameNuvalent
Listing DateJul 29, 2021
Issue Price17.00
Founded2017
CEODr. James R. Porter, PhD
MarketNASDAQ
Employees92
Fiscal Year Ends12-31
AddressOne Broadway,14th floor
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142
Phone1-857-357-7000

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Matthew Shair, PhD
  • Director, Scientific Founder and Head Scientific Advisor
  • 688.18K
  • Dr. James R. Porter, PhD
  • Director, Chief Executive Officer and President
  • 9.38M
  • Dr. Deborah Miller, J.D.,PhD
  • Chief Legal Officer and Secretary
  • --
  • Darlene Noci, A.C.I.S.
  • Chief Development Officer
  • --
  • Alexandra Balcom, M.B.A.
  • Chief Financial Officer, Principal Accounting Officer and Treasurer
  • 3.54M
  • Dr. Christopher D. Turner, M.D.
  • Chief Medical Officer
  • 3.60M
  • Dr. Joseph Pearlberg, M.D.,PhD
  • Independent Director
  • 494.00K
  • Dr. Michael L. Meyers, M.D.,PhD
  • Independent Director
  • 494.36K
  • Dr. Emily Drabant Conley, PhD
  • Independent Director
  • 495.90K
  • Dr. Andrew A. F. Hack, M.D.,PhD
  • Independent Director
  • 495.68K
  • Anna Protopapas
  • Independent Director
  • 523.18K
  • Dr. Sapna Srivastava, PhD
  • Independent Director
  • 503.18K
  • Dr. D. Gary Gilliland, M.D.,PhD
  • Independent Director
  • 495.68K
  • Dr. Cameron A. Wheeler, PhD
  • Independent Director
  • 499.45K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data